Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment

This study investigated the risk factors associated with infusion-related reactions (IRRs) in B-cell lymphoma patients receiving obinutuzumab. A retrospective analysis of Peking Union Medical College Hospital patients (January 2021-December 2024) was conducted to examine factors between patients experiencing IRRs (n = 44) and those without (n = 56). Parameters included gender, age, histological subtype, treatment status, Ann Arbor staging, extranodal/bone marrow involvement, bulky disease, splenomegaly status, serum lactate dehydrogenase (LDH), beta-2 microglobulin (β₂MG) concentrations, and lymphocyte count. 100 patients (48 men, 52 women) with a mean age of 55.7 years (range: 44-67) received obinutuzumab. Univariate analyses showed higher prevalence of bone marrow involvement and splenomegaly in the IRR group. Median LDH (235 vs. 195) and β₂MG (4 vs. 3) levels pre-treatment were significantly elevated in the IRR group (P < 0.05). Multivariate analysis identified splenomegaly and pre-treatment LDH levels as IRR risk factors. This research assists in predicting IRRs to improve patient outcomes.